Thrombophilia screening in our cohort found a 5% rate of FVL which was lower than rates in similar cohorts (7.2–17%), and other thrombophilias such as PT gene mutation (2.0%) and APLS (1.4%) were comparatively much lower in our cohort compared to other RM cohorts in a systematic review (Van Dijk et al., 2020), but were in keeping with a more recent cohort study which demonstrated rates of 2.9% and 0.5% for PT gene mutations and APLS, respectively (Shehata et al., 2022). The gene discussed is F2; the disease is thrombophilia.